By Tom Zanki (July 25, 2022, 8:49 PM BST) -- Cardiovascular disease-focused NewAmsterdam Pharma BV has agreed to go public by merging with special purpose acquisition company Frazier LifeSciences Acquisition Corp. in a deal, guided by three firms, that values the biotechnology startup at $326 million.
Netherlands-based NewAmsterdam will trade on the Nasdaq under the symbol "NAMS" before year's end, if the merger goes through as planned. The agreement calls for infusing NewAmsterdam with $235 million in fresh proceeds through an additional financing round known as a private investment in public equity, or PIPE.
Covington & Burling LLP is representing NewAmsterdam while Goodwin Procter LLP is counseling Frazier LifeSciences. Kirkland &...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!